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Abstract
P-type ATPases catalyze the active transport of cations and phospholipids across biological
membranes. Members of this large family are involved in a range of fundamental cellular
processes. To date, a substantial number of P-type ATPase inhibitors have been character-
ized, some of which are used as drugs. In this work a library of natural compounds was
screened and we first identified curcuminoids as plasmamembraneH+-ATPases inhibitors
in plant and fungal cells. We also found that some of the commercial curcumins contain sev-
eral curcuminoids. Three of these were purified and, among the curcuminoids, demethoxy-
curcumin was the most potent inhibitor of all tested P-type ATPases from fungal (Pma1p;
H+-ATPase), plant (AHA2; H+-ATPase) and animal (SERCA; Ca2+-ATPase) cells. All three
curcuminoids acted as non-competitive antagonist to ATP and hencemay bind to a highly
conserved allosteric site of these pumps. Future research on biological effects of commer-
cial preparations of curcumin should consider the heterogeneity of the material.
Introduction
P-type ATPases constitute a large superfamily of enzymes that carry out pivotal processes in all
kingdoms of life by pumping specific cations or phospholipids across lipid bilayers at the
expense of one ATP molecule per cycle [1–5]. The characteristic structural features of the cata-
lytic subunit of P-type ATPase are three cytosolic domains, comprising an actuator (A), a
nucleotide binding (N), and a phosphorylation domain (P) that together with a multispan
transmembrane domain, and in some cases additional regulatory cytosolic domains (R) at the
N- or C-terminal ends [6–11] make up the pump functional unit. They are classified into five
major families, P1 to P5-ATPases, which are further subdivided into subgroups based on their
sequencemotifs and transport specificity [1, 2, 12]. A hallmark of the P-type ATPases is the
presence of an aspartic acid residue in a highly conservedmotif DKTGT of the P-domain,
which is phosphorylated by ATP during the reaction cycle [2–4, 13]. Some P-type ATPases are
associated with transport of essential micronutrients such as Zn2+ and Cu2+(P1B-ATPases)
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and Ca2+ (P2A and P2B-ATPases). Cation transport by others generates an electrochemical
gradient that in some cases can be used for secondary active transport e.g. plasma membrane
(PM) H+-ATPases in plants and fungi (P3A) and Na+/K+-ATPases in animals (P2C), and for
active transport of lipids (P4-ATPases) [2, 3, 14, 15]. Because of their critical role in the regula-
tion of cellular metabolism,malfunctions of P-type ATPases are associated with a number of
widespread diseases [16, 17].
Due to their important role in health and disease there is considerable interest in identifica-
tion of drugs targeting P-type ATPases and, to date, a substantial number of P-type ATPase
inhibitors have been synthesized or identified from natural sources [17]. Omeprazole is an
example of a synthetic drug that is used to treat dyspeptic conditions and ouabain is a well
known natural compound used to treat congestive heart failure [18, 19]. Mipsagargin, a pro-
drug of thapsigargin, a specific inhibitor of the sarco/encoplasmatic Ca2+-ATPase (SERCA),
has in clinical trials showed promising effects against hepatocellular carcinoma [20]. Recently
an allosteric activator of SERCA has been shown to lower fasting blood glucose, improve glu-
cose tolerance and ameliorate hepatosteatosis in ob/obmice [21].
Fungal P-type ATPases such as the PMH+-ATPase are considered as attractive targets for
the development of new antifungal agents [22–24]. The potential of such agents might include
preservation of food and conservation of crops. At the present, however, no promising lead
compound has been found [17, 25–27].
Inhibition of plant PMH+-ATPase directly affects closure of the stomatal pores, which is
used as a protective measure to help plants overcome extreme stress, such as drought, salinity
or invasions of pathogens [28–32]. A well-describedmodulator of the PMH+-ATPase in the
guard cells surrounding the stomatal pore through which plants breath is the fungal toxin fusi-
coccin [33, 34]. In conclusion, identification and characterization of inhibitors of P-type
ATPases can be expected to be valuable for the discovery of drug leads and of new agents to
protect plants and crops towards infections and for further studies on the structure and func-
tion of the P-type ATPase.
Turmeric rhizomes obtained from either Curcuma longa L. or C. zanthorrhiza Roxb. have
been used in traditional Indian (Ayurveda), Arabian and Chinesemedicine for millennia [35,
36]. The rhizomes are still included in the European Pharmacopoeia. The coloring and biologi-
cal activities have been related to the presence of mainly curcuminoids with curcumin (CM, 1),
demethoxycurcumin (DMCM, 2), bisdemethoxycurcumin (BDCM, 3) as the main constituents
and small amounts of other curcuminoids like cyclocurcumin [37, 38]. Even though some
methods have been developed to separate these compounds on a preparative as well as an ana-
lytical scale, most commercially available samples consist of a mixture of curcuminoids [39–
41]. Despite that the chemical community has been aware of the presence of several curcumi-
noids, the biological community has only to a limited extent paid attention to this fact when
examining the biological activities of curcumin preparations.
Several publications assign the biological activity of turmeric rhizomes to CM, the main
component of curcumin preparations. CM is believed to possess antibacterial and antifungal
activity [42], to have antimalarial effects as well as serving in protection against other parasites
[43, 44]. In a mouse model for Alzheimers disease CM decreases the level of oxidized proteins
and interleukin 1-β [45]. A number of potential target molecules for CM have been identified
such as growth factors, transcription factors, protein kinases, other enzymes (such as cyclooxy-
genase 2 and 5 lipoxygenase) [36] as well as P-type-ATPases [46–49]. Curcumin is undergoing
phase I clinical trials as an adjuvant to improve the effectiveness of chemotherapeutic against
breast cancer [50].
In our efforts to screen for small molecule inhibitors of P-type ATPases, and in particular
PMH+-ATPases, we screened commercial curcumin preparations. An analysis of the product
Demethoxycurcumin as P-Type ATPase Inhibitor
PLOSONE | DOI:10.1371/journal.pone.0163260 September 19, 2016 2 / 19
revealed that demethoxycurcumin (DMCM), one of the major curcuminoids in turmeric
accounts for 15–20%, CM for about 60% and BDCM for about 5%. Many studies have used
commercial curcumin preparations apparently without paying attention to the heterogeneity
of the material. We have examined in detail the effects of the different curcuminoids CM,
DMCM and BDCM. The compounds were tested on PMH+-ATPases from plant (AHA2),
yeast (Pma1p) and the Ca2+-ATPase (SERCA), and they were all found to inhibit these P-type
pumps as noncompetitive ATP antagonists. Furthermore, we were able to demonstrate anti-
growth effects by DMCM on Saccharomyces cerevisiae. This effect is likely to be caused by the
inhibition of the essential PMH+-ATPase.
Materials andMethods
Chemical Materials
Curcumin (cat #C7727), dibenzylideneacetone (cat#246425) and 6-shogaol (cat #39303) were
purchased from Sigma-Aldrich.
Yeast Strain and Plasmids
The S. cerevisiae strain RS-72 (MATa ade1-100 his4-519 leu2-3, 112) [51] was transformed
according to the lithium acetate/single-stranded carrier DNA/polyethylene glycol method [52],
and cultured essentially as describedpreviously [53]. In RS-72, the promoter of the endogenous
yeast PMH+-ATPase PMA1 gene was replaced by the galactose-dependentGAL1 promoter.
This strain grew in media containing galactose, whereas growth in glucose-basedmedium
requires the complementation of the yeast PMH+-ATPase with a functional PMH+-ATPase
expressed from a plasmid. A 2-micron yeast expression vector was used for expression of dif-
ferent versions of the Arabidopsis thaliana PMH+-ATPase AHA2 (pMP 1625); a 92-amino
acid C-terminal truncatedmutation, aha2Δ92 (pMP 132); or the wild-type S. cerevisiae PM
H+-ATPase PMA1 (pMP 400) placed under the control of the PMA1 promoter [54, 55]. The
use of RS-72 allows for purification of microsomes with a very low endogenous ATPase activity
compared to RS-72 transformed with an H+-ATPase carrying plasmid [53, 56].
Purificationof PlasmaMembraneH+-ATPases
Yeast expressing AHA2 and Pma1p PMH+-ATPase, respectively, were grown and harvested
essentially as described [57]. The cells were grown with glucose as carbon source in order to
ensure than no endogenous plasma membrane H+-ATPase is expressed. Microsomes and
plasma membranes were isolated [57] with all manipulations performed at 4°C. The final pel-
lets containing the isolated membranes were collected and homogenized in GTED20 buffer
(20% [v/v] glycerol, 10 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 1 mMDTT) and stored
at—80°C.
Purificationof Spinach PlasmaMembrane
Baby spinach (Spinacia oleracea) leaves (50 g) were cut into small pieces and homogenized.
Subsequently plasma membranes were isolated by two-phase partitioning according to [58].
Plasma membranes were collected and homogenized in the phase buffer containing 330 mM
sucrose, 5 mM potassium phosphate pH 7.8, 2 mMKCl, 0.1 mM EDTA, and 1 mMDTT and
stored at—80°C.
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Procedures for Experimentswith SERCA
Sarcoplasmic reticulum vesicles, prepared from the leg and back muscles of rabbits, were used
to obtain purified SERCA1a by extractionwith a low concentration of deoxycholate according
to established methods [59]. The resulting membrane fragments were used for enzymatic
assays to test the effect of the curcuminoid compounds on ATP hydrolysis spectrophotometri-
cally by NADH oxidation with an ATP regenerating system [60].
Screening of Chemical Library
A number of 160 compounds were chosen from an in-house library of natural products. The
compounds represent a diversity of chemical structures and physicochemical properties impor-
tant for drugs, such as molecular weight< 500, clogP< 5 and tPSA< 100 [61]. All the tested
compounds are listed in S1 Fig. Stock solutions of these compounds (10 mM) were prepared in
50% of DMSO. The compounds were tested up to 100 μM final concentration. Compounds
that inhibited PMH+-ATPase activity more than 50 percent of the control were selected and
retested at lower concentrations.
Isolation of Curcumin Analogs
Curcumin (CM, 1), demethoxycurcumin (DMCM, 2), bisdemethoxycurcumin (BDCM, 3) and
1,5-dihydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-4,6-heptadien-3-one (6) were purified as
previous described [39, 62] (Fig 1). Tetrahydrocurcumin (5), 1,7-bis(3',4'-dimethoxyphenyl)-
4,4-dimethyl-1,6-heptadien-3,5-dione (7) and 1-(3',4'-dimethoxyphenyl)-4,4-dimethyl-7-(4'-
methoxyphenyl)-1,6-heptadien-3,5-dione (8) were synthesized as described by Takeuchi et al.
[63] (Fig 1). The compounds were dissolved in DMSO and stored as small aliquots at—20°C.
PMH+-ATPase Assays
ATPase activity was determined by the Baginski assay as describedpreviously [64] using
2–5 μg of PM protein. The assays were performed at 30°C in 300 μL volumes with 3 mMATP,
pH 6.5, for determination of AHA2 activity, or with 5 mMATP, pH 5.9 for Pma1p activity.
The assay medium 20 mMMOPS, 50 mMKNO3 (to inhibit vacuolar ATPase), 5 mMNaN3
Fig 1. Curcumin analogsemployed in this study. Curcumin (Sigma-Aldrich)was initially identifiedas a hit in an in vitro screen for
inhibitors of the plasmamembrane H+-ATPase. Curcumin (CM, 1) demethoxycurcumin (DMCM,2), bisdemethoxycurcumin (BDCM,3)
and 1,5-dihydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-4,6-heptadien-3-one (6) were then purifiedas previous described [39, 62].
6-shogaol (4) and dibenzylideneacetone (9) were obtained fromSigma-Aldrich. Tetrahydrocurcumin (5), 1,7-bis(3',4'-dimethoxyphenyl)-
4,4-dimethyl-1,6-heptadien-3,5-dione (7) and 1-(3',4'-dimethoxyphenyl)-4,4-dimethyl-7-(4'-methoxyphenyl)-1,6-heptadien-3,5-dione (8)
were synthesized as previously described in the literature[63].
doi:10.1371/journal.pone.0163260.g001
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(to inhibit mitochondrial ATPase), 3.5 mMNa2MoO4 (to inhibit acid phosphatase), 1 mM
Mg2+ free in solution, and the indicated concentrations of MgATP. IC50 values for compound
inhibition were determined by pre incubating PM with different concentrations of compound
for 30 min at room temperature. For kinetics studies, the concentration of ATP was varied
between 0.125 and 8 mM using an ATP regenerating system (5 mM phosphoenolpyruvate and
50 μg/mL pyruvate kinase).
Proton Pumping Assay
Inside-out vesicles were created from spinach plasma membranes by adding the detergent Brij-
58 to the buffer. Proton transport into the vesicles was determined as described [58, 64] by
monitoring fluorescence quenching (excitation at 412 nm, emission at 480 nm) of 9-amino-
6-chloro-2-methoxyacridine (ACMA). The reactionmedium contained 20 mMMOPS-KOH,
pH 7.0, 40 mMK2SO4, 25 mMKNO3, 2 mMATP, 1 μM ACMA, 60 nM valinomycin and
0.05% (w/v) Brij-58. Proton pumping reactions were started by the addition of MgSO4 to a
final concentration of 2 mM, and the proton gradient was collapsed by the addition of 10 μM
nigericin.
Drop Tests
Transformed yeast cells, cultured on synthetic galactose (SG) agar medium supplemented with
adenine 40 μg/mL and L-histidine 20 μg/mL (SGAH plates) for 3 days at 30°C, were suspended
in H2O to 1x solution (OD660 = 1). Serial dilutions of 0.1, 0.01, 0.001 x of the cells were then
prepared and spotted adjacently onto synthetic minimal media plates containing either 2%
galactose or 2% glucose at pH 5.5 (SGAH or SDAH), incorporated with different concentra-
tions of tested compound. Growth results were recorded after incubation for 3 days at 30°C.
Minimum inhibitory concentrations (MIC values) were determined as the lowest concentra-
tions of compounds where no visible growth of cells was observed.
Protein Determination
Protein concentrations were determined by the method of Bradford employing bovine serum
albumin as a reference [65].
Kinetic and Dose-ResponseAnalysis
The kinetic of inhibition for DMCMwas determined by monitoring the rate of ATP hydrolysis
reaction in the presence of increasing ATP substrate concentration. All kinetic data were gath-
ered from experiments performed in the cuvette-based assay, as described above. The data
were used in Hanes-Woolf analysis followed by fitting to the appropriate Michaelis-Menten
inhibition equation (competitive, noncompetitive, uncompetitive, or mix type inhibition). The
kinetic parameters Vmax, Km, Ki were estimated by nonlinear regression using GraphPad Prism
5.0 (GraphPad Software Inc.). For evaluation of inhibitor potency, IC50 values were calculated
by using the equation:
A ¼
100
1þ 10ðLogIC50   LogCÞH
whereA is the observed% ATPase activity in the presence of compound; C, the compound
concentration; IC50, the concentration that caused 50% inhibition of the maximal compound
effect; andH, the slope factor.
Demethoxycurcumin as P-Type ATPase Inhibitor
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Statistics
All experiments were performed at least three independent times, each with three replicates.
Values are presented as mean ± S.E.M. unless otherwise stated. P-values were calculated one-
or two-way analysis of variance (ANOVA) followed by Bonferroni post-hoc testing using
GraphPad Prism 5.0. P< 0.05 was considered statistically significant. , p< 0.05; , p< 0.01;
, p< 0.001.
Results
Screening of a Chemical Library for Inhibitors of PMH+-ATPases
A library of 160 natural products was screened for the ability to inhibit fungal (Pma1p) and
plant (AHA2) PM H+-ATPase. The selected library encompassed a diversity of structures
possessing a broad range of physicochemical properties important for drug action. From the
initial data, curcumin (Sigma-Aldrich, cat #C7727) was identified as the best hit, showing
more than 95% of the inhibition at 100 μM as compared to the control (S1 Fig). An analysis
of the commercially available curcumin revealed that the product consisted of approximately
80% of CM, 15% of DMCM and a number of minor curcuminoids including BDCM as dem-
onstrated by HPLC (S2 Fig). This encouraged us to purify various curcuminoids (CM,
DMCM and BDCM) present in the commercial curcumin for establishing the range of
potency for each constituent.
Effects of Curcumin Analogs on the PMH+-ATPases Activity
A series of nine curcumin analogs (Fig 1), which have different substitution patterns on the
aryl moiety (1, 2, 3), different numbers of conjugated double bonds (1, 5, 6), phenol groups (1,
4), or the central keto-enol functionalities (1, 4, 9) or blocked enolization (1, 7, 8) [66] were
evaluated for their potential to inhibit PMH+-ATPases. The inhibitory effects of each com-
pound on PMH+-ATPases activity were determined experimentally at a final concentration of
50 μM on recombinant plant (AHA2) or fungal (Pma1p) PMH+-ATPase enzyme, respectively.
Only three of the curcumin analogs: CM, DMCM and BDCM significantly inhibited these
enzymes (Fig 2A), among which DMCM (2) exhibited the most pronounced effect, while CM
and BDCMwere about half as effective. Interestingly these compounds were equally effective
inhibitors of both plant and yeast PMH+-ATPase enzymes, whereas the other tested analogs
did not exhibit any effect on AHA2 and Pma1p activity (Fig 2A). These preliminary structure
activity observations suggest that the central keto-enol moiety and surrounding conjugated
double bonds are chemical features important for the inhibitory activity towards the PMH+-
ATPases.
InhibitoryEffects on PMH+-ATPases by DMCM
To further evaluate the specific inhibitory activity of the three analogs on PM H+-ATPase
activity, concentration response curves were generated (Fig 2B). The activity of AHA2 was
reduced by DMCM in a concentration-dependent manner with IC50 of 18.7 μM, which is a
more potent effect than that of CM and BDMC (IC50, 60.4 and 76.7 μM, respectively)
(Table 1). The same pattern of inhibitory potencies was observed for Pma1p with IC50 val-
ues of 28.9, 76.1 and 90.6 μM, respectively (Fig 2B and Table 1). Interestingly, the structure
of DMCM containing a methoxy moiety at only one of the two phenyl rings significantly
enhanced the inhibitory activity (IC50 value) by a 2- to 4-fold lower value, in comparison to
CM which has two p-hydroxy-m-methoxyphenyl rings or BDCMwith only p-hydroxyphe-
nyl rings. The inhibition curves were fitted with a variable slope factor H. The H factor for
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DMCM inhibition of AHA2 and Pma1p was 2.4 and 1.5 respectively, in contrast to the
numbers for CM and BDCM that were close to 1. This suggests a cooperative binding of
DMCM.
Fig 2. Curcumin analogs inhibit plasmamembraneH+-ATPases activity in a dose dependentmanner. (A) ATPase activity
measured on yeast plasmamembranes from yeast strains expressing eitherA. thalianaPMH+-ATPase isoformAHA2 (left panel)
or the endogenous yeast plasmamembranePma1p (right panel) in the presence of 50 μMof the curcumin analogs, compounds
1–9, or vanadate, a P-type ATPase inhibitor. Values aremean ± S.E. (n = 3). Student’s t tests:*, p < 0.05; **, p < 0.01; ***,
p < 0.001 relative to the control. (B) Dose-dependent inhibition of H+-ATPase activity of AHA2 (left) and Pma1p (right).
Experiments were carried out in triplicatesat different concentrations of CM (1), DMCM (2) and BDCM (3). Data were analyzed by
using nonlinear regression tool and fitted to log(inhibitor) vs. normalized response (variable slope) for determination of IC50
values.
doi:10.1371/journal.pone.0163260.g002
Table 1. IC50 values for compounds 1–3 in ATP hydrolysis assays.
Compound AHA2 Pma1p SERCA
CM (1) 60.4 ± 1.1 76.1 ± 1.0 3.9 ± 0.4
DMCM (2) 18.7 ± 1.0 28.9 ± 1.0 2.6 ± 0.9
BDCM (3) 76.7± 1.1 90.6 ± 1.1 9.4 ± 1.6
All values are presented as the mean of three independent experiments ± S.E., and indicated in μM.
doi:10.1371/journal.pone.0163260.t001
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Effects of Curcuminoids on Proton Transport in PlasmaMembrane
Vesicles fromSpinach Leaves
PMH+-ATPases utilize the energy released from ATP phosphorylation followed by hydrolysis
to pump protons across the plasma membrane generating an electrochemical gradient required
for nutrient and water uptakes by plant and fungi [28, 34]. Because of the tight coupling
betweenATP hydrolysis and proton transport [67, 68], we next studied the effects of curcumi-
noids on H+ pumping activity by using PM vesicles isolated from spinach leaves. Fig 3 shows
the quenched fluorescence caused by proton accumulation inside the vesicles in response to
treatment with the three curcuminoids. Again DMCM exhibited the strongest effect compared
to CM and BDCM. The H+ pumping activity was dramatically reversed in the concentration
range 5–20 μM of DMCM. The order of efficiency among the three compounds (Fig 3) was
similar to the above ATP hydrolysis results and therefore strongly confirms the inhibition
effects on PMH+-ATPases of these compounds.
Mechanismof DMCM Inhibition
To characterize the mode of ATPase inhibition by DMCM, we performed enzyme kinetics
with increasing concentrations of the substrate ATP (0.125–8 mM) in the presence of various
concentrations of DMCM (0, 10, 20, 30 and 40 μM). Total ATP hydrolysis activity of AHA2
and Pma1p is depicted in Fig 4. An initial Hanes-Woolf plot indicated a non-competitive inhi-
bition (not shown) the curveswere therefore fitted by the appropriate nonlinear regression
(with noncompetitive equation) using GraphPad Prism.We found that the apparent Km values
for ATP remained at a constant level, independent of the addition of DMCM. This was
observed for both AHA2 and Pma1p with Km values of 0.4 and 4.1 μM, respectively. The Vmax
values, on the other hand, were decreased due to increasing concentrations of DMCM (Fig 4
and Table 2). We estimated the Ki to be 14.7 and 27.7 μM for AHA2 and Pma1p respectively
(Table 3), corresponding to the previously estimated IC50 values. These kinetic data suggest
that DMCM behaves as a noncompetitive inhibitor of ATP.
Effects of DMCMon SERCA Activity
AHA2 and Pma1p are members of the P-type ATPase superfamily to which SERCA also
belongs. Previously the effect of commercial curcumin on SERCA has been broadly investi-
gated [46–48]. In none of these studies, however, has the homogeneity of the purchased CM
been verified. Analysis of CM batches bought from different vendors revealed that many prod-
ucts consisted of CM-DMCM-BDCM in the approximate ratio of 80:15:5 (S2 Fig). All of this
prompted us to analyze the inhibitory effect of the three curcumin analogs found in curcumin
purchased from Sigma on SERCA activity. As the result of this test we could show that DMCM
treatment had the most potent inhibitory effect on the ATPase activity of the purified and
leaky preparations of SERCA (which we used to avoid complicating effects of intravesicular
accumulation of Ca2+). From these experiments we extract an IC50 value of 2.6 μM from the
dose dependent response curve in comparison to CM and BDCM (IC50, 3.9 and 9.4 μM,
respectively) (Fig 5 and Table 1). Thus the inhibitory effects of these compounds on SERCA
were found to be stronger, but with retention of the same order of potencies as observedon
AHA2 and Pma1p pumps. These data, in conjunction with the report of an inhibitory effect of
curcumin on Na+/K+-ATPase [49] suggest that DMCMmay modulate different members of P-
type ATPases in vitro by a commonmechanism binding to a highly conserved region [69].
Demethoxycurcumin as P-Type ATPase Inhibitor
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Effects of Curcuminoids on Yeast Growth
As PMH+-ATPases are essential for the growth of fungi, we used the yeast strain RS-72 as a
model to test the potency of the curcuminoids. In S. cerevisiae strain RS-72, expression of the
Fig 3. Curcumin analogs also inhibit proton pumping. (A-C) Protonmediated accumulation of ACMA in
spinach plasmamembrane vesicles after incubatingwith various concentrations of CM (1), DMCM (2) and BDCM
(3). ATP stimulatedH+-pumping is initiated upon addition of MgSO4. One representative of three independent
experiments is shown for each compound (left panels). Proton transportactivity was determined as initial rates of
fluorescence quenching of ACMA probe (right panels). Values aremean ± S.E. (n = 3). Student’s t tests:*, p < 0.05;
**, p < 0.01; ***, p < 0.001 relative to the control.
doi:10.1371/journal.pone.0163260.g003
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PLOSONE | DOI:10.1371/journal.pone.0163260 September 19, 2016 9 / 19
Fig 4. Kinetic analysis of PMH+-ATPases inhibitionby DMCM. ATP hydrolysis rate was plotted as function of
[ATP] in the presence of the indicated amounts of DMCM;Yeast expressingA. thalianaPMH+-ATPase isoform
AHA2 (A) and the endogenous yeast isoformPma1p (B). Error bars represent standard errors of the mean for three
independent trials.
doi:10.1371/journal.pone.0163260.g004
Table 2. Effect of DMCMon the ATP hydrolysis of the PMH+-ATPases.
Demethoxycurcumin (μM) AHA2 Pma1p
Km (mM) Vmax (μM/mg/min) Km (mM) Vmax (μM/mg/min)
0 0.36 ± 0.05 0.64 ± 0.02 3.55 ± 0.48 0.98 ± 0.06
10 0.43 ± 0.06 0.46 ± 0.02 5.85 ± 1.45 1.00 ± 0.13
20 0.60 ± 0.08 0.35 ± 0.01 4.06 ± 0.65 0.63 ± 0.05
30 0.49 ± 0.08 0.19 ± 0.01 3.85 ± 0.71 0.48 ± 0.04
40 0.44 ± 0.09 0.11 ± 0.01 4.09 ± 0.89 0.39 ± 0.04
The ATP hydrolytic activity was measuredwith various concentrations of ATP and the kinetic constants (Vmax, Km values) were determined from nonlinear
regression of the Michaelis-Menten equation. Values are mean ± S.E. (n = 3).
doi:10.1371/journal.pone.0163260.t002
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endogenous PMH+-ATPase PMA1 is dependent on the addition of galactose to the media
enabling the possibility of expressing and testing other PM H+-ATPase homologues. RS-72
transformed with an empty vector (as control) is not able to grow in glucose containing media
(Fig 6). RS-72 expressing eitherArabidopsis homologues (wild-type:AHA2 and a truncated
mutation: aha2Δ92) or wild-typePMA1 from S. cerevisiae were grown on media containing
increasing concentrations of the three compounds in question. The enzyme aha2Δ92 is an acti-
vated form of AHA2 due to the removal of an autoinhibitory domain. Yeast cells dependent on
heterologously expressed aha2Δ92 grow better than cells expressing wild-typeAHA2, which
grow poorly compared to yeast expressing wild-type Pma1p. All the tested strains showed sen-
sitivity to the added compounds (Fig 6). Again DMCMwas the most effective inhibitor com-
pared to CM and BDCM.Minimum inhibitory concentrations (MIC values) were
Table 3. Effects of compounds 1–3 on PMH+-ATPases in vitro and in in vivodrop test assay.
Compound In Vitro Drop Test
AHA2 (Ki, μM) Pma1p (Ki, μM) AHA2 (MIC, μM) Pma1p (MIC, μM)
CM (1) ND ND 40–50 60–70
DMCM (2) 14.7 ± 0.7 27.7 ± 1.2 20–30 40–50
BDCM (3) ND ND 200–210 210–220
The inhibition constants (Ki values) were estimated by fitting data to a nonlinear regression analysis using noncompetitive model. The values are mean ± S.
E. (n = 3) and ND indicates not detected.Minimum inhibitory concentrations (MIC values) were determinedby the lowest concentrations of CM (1), DMCM
(2) and BDCM (3) where no visible growth of cells was observed.
doi:10.1371/journal.pone.0163260.t003
Fig 5. Dose-dependent inhibitionof SERCACa2+-ATPase activity. Inhibition of ATP hydrolytic activity by
addition of increasing amounts of compounds. Experiments were carried out in triplicateat different concentrations
of CM (1), DMCM (2) and BDCM (3). Data were analyzed by using nonlinear regression tool and fitted to log
(inhibitor) vs. normalized response (variable slope) for determination of IC50 values.
doi:10.1371/journal.pone.0163260.g005
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approximately 30, 50 and 200 μM for DMCM, CM and BDCM, respectively (Fig 6 and
Table 3) demonstrating a convincing positive correlation between the enzyme assay and the
growth experiments.
Discussion
PMH+-ATPase Inhibition and the Antifungal Effect of Curcuminoids
Curcuminoids originate from rhizomes of C. longa. The dried and grounded rhizomes are
commonly used as spices in food and in health products. Many studies have reported that the
curcuminoids possess antifungal activity [42], and also have synergistic properties with other
well known agents [70, 71]. However, very few studies have compared the activities of the three
Fig 6. Drop tests showing the sensitive responseof S. cerevisiaemutant cells (encodingAHA2, aha2Δ92 or Pma1p) to compounds
1–3. Serial dilutions of the yeast cultures are spotted on galactose (YPG) or glucose (YPD)media containing the indicated concentrations of CM
(1), DMCM (2) or BDCM (3). Growth results were recorded after incubation for 3 days at 30°C. Results shown are representative data of three
independent experiments for each compound.
doi:10.1371/journal.pone.0163260.g006
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major curcuminoids. The present study provides insight into the mode of action of three cur-
cuminoids and demonstrates an inhibitory effect on Pma1p, correlated with reduced fungal
growth. This result is fully consistent with a recent report defining the pH differences in Can-
dida culture medium in presence and absence of CM, which suggested curcumin to regulate
H+- extrusion by PM ATPases [72].
In addition, we show that curcuminoids also inhibit plant PM H+-ATPase. This effect could
be of interest in order to protect plants during pathogenic infections. In plants, several patho-
genic bacteria enter the leaf through the stomatal pore and closure of the stomatal pore by inhi-
bition of the PMH+-ATPase is one of the defense mechanisms exploited by plants upon
recognition of pathogenic bacteria [29–32]. Also pretreatment of plants with curcumin
revealed fungicidal activity towards selected plant pathogenic fungi [73], if this effect was due
to a direct effect on the fungi or the ability to infect via the stomatal pore is not known. The
low toxicity of the curcuminoids towards humans makes them interesting agents for develop-
ments of antifungal agents. The higher activity of DMCMmakes this the most interesting lead
compound to be used in organic agriculture and food preservation.
DMCM Is a Potent SERCA Pump Inhibitor
Inhibitory effects of CM and some of its analogs, including BDCM, on SERCA have been
broadly investigated. In the present study we compared the effect of DMCMwith CM and
BDCMon the basis of Ca2+-ATPase activity per se of the SERCA pump.
Interestingly, DMCM exhibited the strongest effect on SERCA among the tested curcumi-
noids with an IC50 value of 2.6 μM compared to IC50 values of 3.9 and 9.4 μM for CM and
BDCM, respectively. Numerous studies to date have shown the pharmacological safety and
efficacyof CM, however, it exhibits poor bioavailability due to fast metabolism primarily
through reduction followed by conjugation to glucuronic or sulfuric acid [74]. Although the
structural difference betweenCM and DMCM is a minor one (namely the presence or absence
of a methoxy group), the chemical characteristics of DMCM are more stable [75]. Our data
might inspire to future investigations of the performance of DMCM in prostate and colorectal
cancers related to SERCA activity [76, 77].
StructureActivity Relationships of Curcuminoids on ATPase Activity
In the current study, we have investigated the structure activity relationship of curcumin ana-
logs and discoveredmolecular characteristics important for the effects against ATPase. The
study has included the role of the hydroxyl aryl moiety, conjugated double bonds and the cen-
tral keto-enol moiety. Although a previous study on SERCA has emphasized the importance of
phenolic -OH at the 4 position and the non-essential role of o-methoxy group on the aryl ring
[46], our data showed the more complicated interaction with this methoxy group. DMCM
with only one methoxy group significantly enhanced the inhibitory activity, whereas CM and
BDCMpossessing two or no methoxy groups, respectively, were less active. This findingmight
be related to the asymmetrical nature of DMCM in contrast to CM and BDCM. In DMCM the
two oxygen atoms at the aliphatic chain (O-3 and O-5) are not chemically identical and form a
predominant tautomer B2 [78]. The o-methoxy group influences the electron density on the
central keto-enol group, which in turn might affect its binding ability to ATPase proteins.
CurcuminoidsAre General P-Type ATPase Inhibitors
Inhibitors of P-type ATPases are important drugs [17]. Of particular importance are digoxin,
ouabain [18, 19, 79], thapsigargin [80, 81] and cyclopiazonic acid [82], which are all derived
from natural products. Turmeric, a spice with multiple pharmacological utilities [83] has been
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shown to possess a mild inhibitory effect on Na+/K+-ATPase [49], mammalianCa2+-ATPase
[46–48] and a malaria parasite orthologue PfATP6 [84]. In this study we have reported
DMCM as a potent inhibitor of SERCA (P2 type) and PMH+-ATPase (P3 type). These results
and previous work on both SERCA [46–48] and Na+/K+-ATPase [49] lead us to consider
DMCM and other curcuminoids as general P-type ATPase inhibitors that also modulate other
members of the P-type ATPase superfamily. Our kinetic study revealed that DMCM is a non-
competitive antagonist to ATP and hence may bind to a highly conserved allosteric site of
these pumps. This is accordance with the previous findings for CM binding on SERCA [46–
48]. Additionally our data suggested that DMCMmight bind in a cooperativemanner or that
two binding sites are present. A similar observation is made in [48] where the authors suggest
that binding of curcumin to the Ca2+-ATPase induces a conformational change, which then
blocks the ATP binding.
In conclusion, our study reveals that curcuminoids target P-type ATPases present in fungi,
plants and animals, and have antifungal properties. In spite of the inhibition of P-type ATPases
they are not toxic for mammals [85], which can be explained by fast metabolism into glucuro-
nides and sulfates [74, 86]. The structure activity relationship analysis of curcumin analogs
against these ATPases provides crucial information for drug design and discovery process.
Among the active curcuminoids present in the commercial preparation of curcumin,DMCM is
the most potent inhibitor of all tested P-type ATPases. Future studies on biological effects of cur-
cuminoids thus should consider the heterogeneity of the commercial samples of the compounds.
Supporting Information
S1 Appendix. 1H NMR and 13C NMR spectra for CM in acetone-d6.
(TIF)
S2 Appendix. 1H NMR and 13C NMR spectra for DMCM in acetone-d6.
(TIF)
S3 Appendix. 1H NMR and 13C NMR spectra for BDCM in acetone-d6.
(TIF)
S1 Fig. Screening of 163 compounds for their ability to inhibit plasmamembraneH+-
ATPase activity. ATPase activity measured in the presence of 100 μM of the indicated com-
pounds. The effect is presented relative to an untreated sample. A sample containing the well-
described inhibitor of P-type ATPases, vanadate, is included as control. Below the diagram all
tested compounds are listed.
(TIFF)
S2 Fig. HPLC analysis of commercially available curcumin.Analytical HPLC profiles of
compounds 1–3 (A-C), and curcumins Sigma #C7727 (D), Abcam #120618 (E) and Aldrich
#238384 (F) were performed using a Waters system: DAD detector 390 nm, column RP C18
(150 x 4.6 mm), flow rate 0.8 mL/min, injection volumn 5 μL of 0.1 mg/min sample solution,
solvent gradient 44.9%MeCN, 55% H2O and 0.1% formic acid to 98.9%MeCN, 1% H2O and
0.1% formic acid over 15 min.
(TIFF)
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